BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015;6:28929-37. [PMID: 26078337 DOI: 10.18632/oncotarget.4325] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Laxmi A, Gupta P, Gupta J. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target. CBM 2019;24:383-93. [DOI: 10.3233/cbm-181601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. J Mol Diagn 2017;19:682-96. [PMID: 28802831 DOI: 10.1016/j.jmoldx.2017.05.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
3 Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist 2016;21:1306-14. [PMID: 27682134 DOI: 10.1634/theoncologist.2016-0148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chan AW, Pan Y, Tong JH, Lung RW, Kwan JS, Chow C, Tin EK, Chung LY, Li H, Wong SS, Chau SL, Chan YY, Mak TW, Ng SS, To KF. Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. J Pathol 2020;251:74-86. [PMID: 32162306 DOI: 10.1002/path.5418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Michal M, Ptáková N, Martínek P, Gatalica Z, Kazakov DV, Michalová K, Stoláriková L, Švajdler M, Michal M. S100 and CD34 positive spindle cell tumor with prominent perivascular hyalinization and a novel NCOA4-RET fusion. Genes Chromosomes Cancer 2019;58:680-5. [PMID: 30938880 DOI: 10.1002/gcc.22758] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
6 De Falco V, Carlomagno F, Li HY, Santoro M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017;31:307-18. [PMID: 28911727 DOI: 10.1016/j.beem.2017.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wu SM, Tsai WS, Chiang SF, Lai YH, Ma CP, Wang JH, Lin J, Lu PS, Yang CY, Tan BC, Liu H. Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for pathogenesis. Sci Rep 2020;10:4526. [PMID: 32161294 DOI: 10.1038/s41598-020-61273-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hechtman JF, Zehir A, Yaeger R, Wang L, Middha S, Zheng T, Hyman DM, Solit D, Arcila ME, Borsu L, Shia J, Vakiani E, Saltz L, Ladanyi M. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Mol Cancer Res 2016;14:296-301. [PMID: 26660078 DOI: 10.1158/1541-7786.MCR-15-0392-T] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
9 Salvi S, Ravetti JL, Arena G, Musso C, Varesano S, Pistillo MP, Canessa PA, Ferro P, Fedeli F, Roncella S. Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma. J Thorac Oncol 2018;13:e12-4. [PMID: 29258668 DOI: 10.1016/j.jtho.2017.09.1957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Kim SC, Hong CW, Jang SG, Kim YA, Yoo BC, Shin YK, Jeong SY, Ku JL, Park JG. Establishment and Characterization of Paired Primary and Peritoneal Seeding Human Colorectal Cancer Cell Lines: Identification of Genes That Mediate Metastatic Potential. Transl Oncol 2018;11:1232-43. [PMID: 30114595 DOI: 10.1016/j.tranon.2018.07.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Takahashi M, Kawai K, Asai N. Roles of the RET Proto-oncogene in Cancer and Development. JMA J 2020;3:175-81. [PMID: 33150251 DOI: 10.31662/jmaj.2020-0021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Graves-Deal R, Bogatcheva G, Rehman S, Lu Y, Higginbotham JN, Singh B. Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget 2019;10:1320-33. [PMID: 30863492 DOI: 10.18632/oncotarget.26663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lee SJ, Hong JY, Kim K, Kim KM, Kang SY, Lee T, Kim ST, Park SH, Park YS, Lim HY, Kang WK, Lee J, Park JO. Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. J Oncol 2020;2020:4659062. [PMID: 32411236 DOI: 10.1155/2020/4659062] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Han Q, Kono TJY, Knutson CG, Parry NM, Seiler CL, Fox JG, Tannenbaum SR, Tretyakova NY. Multi-Omics Characterization of Inflammatory Bowel Disease-Induced Hyperplasia/Dysplasia in the Rag2-/-/Il10-/- Mouse Model. Int J Mol Sci 2020;22:E364. [PMID: 33396408 DOI: 10.3390/ijms22010364] [Reference Citation Analysis]
15 Arai S, Kita K, Tanimoto A, Takeuchi S, Fukuda K, Sato H, Yano S. In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. Oncotarget 2017;8:73766-73. [PMID: 29088743 DOI: 10.18632/oncotarget.17900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 García-Aranda M, Redondo M. Targeting Receptor Kinases in Colorectal Cancer. Cancers (Basel) 2019;11:E433. [PMID: 30934752 DOI: 10.3390/cancers11040433] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
17 Liu W, Li H, Aerbajinai W, Botos I, Rodgers GP. OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma. Oncogene 2021. [PMID: 34675408 DOI: 10.1038/s41388-021-02072-1] [Reference Citation Analysis]
18 Kohno T, Tabata J, Nakaoku T. REToma: a cancer subtype with a shared driver oncogene. Carcinogenesis 2020;41:123-9. [PMID: 31711124 DOI: 10.1093/carcin/bgz184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
19 Levinson S, Cagan RL. Drosophila Cancer Models Identify Functional Differences between Ret Fusions. Cell Rep 2016;16:3052-61. [PMID: 27626672 DOI: 10.1016/j.celrep.2016.08.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
20 Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Clin Colorectal Cancer 2020;19:82-90.e9. [PMID: 32192883 DOI: 10.1016/j.clcc.2019.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Peiris MN, Li F, Donoghue DJ. BCR: a promiscuous fusion partner in hematopoietic disorders. Oncotarget 2019;10:2738-54. [PMID: 31105873 DOI: 10.18632/oncotarget.26837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Staubitz JI, Musholt TJ, Schad A, Springer E, Lang H, Rajalingam K, Roth W, Hartmann N. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. Cancer Genetics 2019;238:10-7. [DOI: 10.1016/j.cancergen.2019.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer 2019;138:124-30. [DOI: 10.1016/j.lungcan.2019.09.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
24 Mulligan LM. GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential. Front Physiol 2018;9:1873. [PMID: 30666215 DOI: 10.3389/fphys.2018.01873] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
25 Kim SY, Oh SO, Kim K, Lee J, Kang S, Kim KM, Lee W, Kim ST, Nam DN. NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. J Cancer 2018;9:3032-7. [PMID: 30210625 DOI: 10.7150/jca.26256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
26 Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016; 22(25): 5668-5677 [PMID: 27433082 DOI: 10.3748/wjg.v22.i25.5668] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
28 Mendes Oliveira D, Grillone K, Mignogna C, De Falco V, Laudanna C, Biamonte F, Locane R, Corcione F, Fabozzi M, Sacco R, Viglietto G, Malanga D, Rizzuto A. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. J Exp Clin Cancer Res 2018;37:84. [PMID: 29665843 DOI: 10.1186/s13046-018-0746-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
29 Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol 2020;15:541-9. [PMID: 31988000 DOI: 10.1016/j.jtho.2020.01.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 27.0] [Reference Citation Analysis]
30 Cerrato A, Merolla F, Morra F, Celetti A. CCDC6: the identity of a protein known to be partner in fusion. Int J Cancer 2018;142:1300-8. [PMID: 29044514 DOI: 10.1002/ijc.31106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
31 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
32 Mondaca S, Yaeger R. Colorectal cancer genomics and designing rational trials. Ann Transl Med 2018;6:159. [PMID: 29911107 DOI: 10.21037/atm.2018.03.27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
33 Fancelli S, Caliman E, Mazzoni F, Brugia M, Castiglione F, Voltolini L, Pillozzi S, Antonuzzo L. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers (Basel) 2021;13:1091. [PMID: 33806299 DOI: 10.3390/cancers13051091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Jin D, Huang K, Peng L, Xu P, Dang Y, Yang J, Chen M, Zhu X, Wei S, Yan J, Zhang G. Circular RNA circDNA2 upregulates CCDC6 expression to promote the progression of gastric cancer via miR-149-5p suppression. Mol Ther Nucleic Acids 2021;26:360-73. [PMID: 34552818 DOI: 10.1016/j.omtn.2021.05.021] [Reference Citation Analysis]
35 Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. Int J Mol Sci 2019;20:E5319. [PMID: 31731495 DOI: 10.3390/ijms20215319] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
36 Chen Z, Zhao Y, Yu Y, Pang JC, Woodfield SE, Tao L, Guan S, Zhang H, Bieerkehazhi S, Shi Y, Patel R, Vasudevan SA, Yi JS, Muscal JA, Xu GT, Yang J. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget 2017;8:104090-103. [PMID: 29262623 DOI: 10.18632/oncotarget.22011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
37 Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L. RET kinase inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat 2017;27:91-9. [PMID: 27646564 DOI: 10.1080/13543776.2017.1238073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
38 Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. Mol Pharmacol 2021;99:435-47. [PMID: 33795352 DOI: 10.1124/molpharm.120.000207] [Reference Citation Analysis]
39 Lawlor RT, Mafficini A, Sciammarella C, Cantù C, Rusev BC, Piredda ML, Antonello D, Grimaldi S, Bonizzato G, Sperandio N, Marchegiani G, Malleo G, Pea A, Salvia R, Mombello A, Mazzoleni G, Nottegar A, Hanspeter E, Riva G, Tomezzoli A, Bencivenga M, de Manzoni G, Pedron S, Paolino G, Mattiolo P, Brosens LA, Silvestris N, Fassan M, Cooke SL, Beer PA, Milella M, Adsay VN, Cheng L, Scarpa A, Luchini C. Genomic characterization of hepatoid tumors: context matters. Hum Pathol 2021;118:30-41. [PMID: 34562502 DOI: 10.1016/j.humpath.2021.09.006] [Reference Citation Analysis]
40 Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol 2018;29:1394-401. [PMID: 29538669 DOI: 10.1093/annonc/mdy090] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
41 Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J, Yan S, Wei G, Oliver JW, Patel R, Multani P, Ladanyi M, Drilon A. Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 2017;23:2981-90. [PMID: 28011461 DOI: 10.1158/1078-0432.CCR-16-1887] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
42 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. [PMID: 28050011 DOI: 10.1038/nrc.2016.126] [Cited by in Crossref: 338] [Cited by in F6Publishing: 307] [Article Influence: 67.6] [Reference Citation Analysis]
43 Morra F, Merolla F, D’abbiero D, Ilardi G, Campione S, Monaco R, Guggino G, Ambrosio F, Staibano S, Cerrato A, Visconti R, Celetti A. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. Lung Cancer 2019;135:56-65. [DOI: 10.1016/j.lungcan.2019.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Song HN, Lee C, Kim ST, Kim SY, Kim NK, Jang J, Kang M, Jang H, Ahn S, Kim SH, Park Y, Cho YB, Heo JW, Lee WY, Park JO, Lim HY, Kang WK, Park YS, Park WY, Lee J, Kim HC. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget 2016;7:19610-9. [PMID: 26909603 DOI: 10.18632/oncotarget.7526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
45 Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 2019;32:1053-64. [PMID: 30723297 DOI: 10.1038/s41379-019-0212-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
46 Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. Dis Model Mech 2020:dmm. [PMID: 33318047 DOI: 10.1242/dmm.047779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Antonescu CR, Dickson BC, Swanson D, Zhang L, Sung YS, Kao YC, Chang WC, Ran L, Pappo A, Bahrami A, Chi P, Fletcher CD. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. Am J Surg Pathol 2019;43:1384-91. [PMID: 31219820 DOI: 10.1097/PAS.0000000000001297] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
48 Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem 2021;64:11747-73. [PMID: 34402300 DOI: 10.1021/acs.jmedchem.0c02167] [Reference Citation Analysis]
49 Bray SM, Lee J, Kim ST, Hur JY, Ebert PJ, Calley JN, Wulur IH, Gopalappa T, Wong SS, Qian HR, Ting JC, Liu J, Willard MD, Novosiadly RD, Park YS, Park JO, Lim HY, Kang WK, Aggarwal A, Kim HC, Reinhard C. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Sci Rep 2019;9:15365. [PMID: 31653970 DOI: 10.1038/s41598-019-51981-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
50 Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C. RET fusions in solid tumors. Cancer Treat Rev 2019;81:101911. [PMID: 31715421 DOI: 10.1016/j.ctrv.2019.101911] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 16.7] [Reference Citation Analysis]
51 Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. J Natl Cancer Inst 2017;109. [PMID: 29370427 DOI: 10.1093/jnci/djx089] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 34.7] [Reference Citation Analysis]
52 Conconi D, Redaelli S, Bovo G, Leone BE, Filippi E, Ambrosiani L, Cerrito MG, Grassilli E, Giovannoni R, Dalprà L, Lavitrano M. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients. Tumour Biol 2016;37:13831-42. [PMID: 27481518 DOI: 10.1007/s13277-016-5181-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Santoro M, Moccia M, Federico G, Carlomagno F. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes (Basel). 2020;11. [PMID: 32326537 DOI: 10.3390/genes11040424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
54 Santos C, Sanz-pamplona R, Salazar R. RET-fusions: a novel paradigm in colorectal cancer. Annals of Oncology 2018;29:1340-3. [DOI: 10.1093/annonc/mdy132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
55 Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 2021:S2405-8033(21)00148-5. [PMID: 34391699 DOI: 10.1016/j.trecan.2021.07.003] [Reference Citation Analysis]
56 Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol 2020;38:1209-21. [PMID: 32083997 DOI: 10.1200/JCO.19.02551] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
57 Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev 2019;81:101912. [PMID: 31715423 DOI: 10.1016/j.ctrv.2019.101912] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
58 Croce S, Hostein I, McCluggage WG. NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms. Genes Chromosomes Cancer 2021;60:147-59. [PMID: 33099837 DOI: 10.1002/gcc.22910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. J Med Chem 2020;63:4506-16. [PMID: 32298114 DOI: 10.1021/acs.jmedchem.9b01336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
60 Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2017;9:551-64. [PMID: 28794806 DOI: 10.1177/1758834017714997] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]